Age-Related Variations in Treatment Patterns for Axial Spondyloarthritis.
| Autor: | Erdogan, Esra Kayacan, Orhan, Kevser, Ulucakoy, Rezan Kocak, Ulusoy, Bahar Ozdemir, Guven, Serdar Can, Atalar, Ebru, Armagan, Berkan, Babaoglu, Hakan |
|---|---|
| Předmět: |
CROSS-sectional method
CONSERVATIVE treatment ADRENOCORTICAL hormones ANKYLOSIS DISEASE management METHOTREXATE LEFLUNOMIDE SEX distribution AGE distribution COLCHICINE ANTIRHEUMATIC agents RETROSPECTIVE studies DESCRIPTIVE statistics CHI-squared test PHYSICIAN practice patterns SULFONAMIDES ANALYSIS of variance SPONDYLOARTHROPATHIES DATA analysis software PATIENTS' attitudes COMORBIDITY DRUG utilization INTERLEUKINS TUMOR necrosis factors CHEMICAL inhibitors |
| Zdroj: | Medical Records; 2024, Vol. 6 Issue 3, p324-328, 5p |
| Abstrakt: | Aim: This study examines treatment patterns and preferences among patients diagnosed with Axial Spondyloarthritis (AxSpA) across different age groups. Material and Method: Ankara Bilkent City Hospital registry enabled a comprehensive cross-sectional analysis of 2,811 patients stratified into three age groups: 18-40, 41-55, and over 55 years. These groups were compared in terms of their treatments. Results: Our findings indicate an increasing prevalence of female patients and comorbidities with age. Medication usage patterns showed a trend towards increased use of Methotrexate and Colchicine with age, while Sulfasalazine and Leflunomide were more commonly prescribed in older age groups. Notably, the use of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs), including anti-Tumor Necrosis Factor (anti-TNF)", "anti-Interleukin (anti-IL) agents, demonstrated a declining trend with advancing age, though not reaching statistical significance. This trend was also reflected in gender-specific treatment distributions, where no significant difference was found in bDMARDs administration among patients over 55 years, contrasting with a higher usage rate in younger male patients. Conclusion: Our study highlights a shift towards more conservative treatment approaches, such as increased conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) use in older patients, likely due to their safety profile and the specific challenges associated with treating older adults, including higher comorbidity rates and medication side effects. These findings emphasize the need for personalized treatment strategies and suggest potential adjustments in clinical practices to better accommodate the aging population, advocating for ongoing research to optimize treatment efficacy and safety for elderly patients with AxSpA. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|